Journal of Family & Community Medicine
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contact us Login 
 

Users Online: 2189 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size

 

 Table of Contents 
REVIEW ARTICLE
Year : 1995  |  Volume : 2  |  Issue : 1  |  Page : 19-26  

Cardiovascular risk and risk reduction: A review of recent literature


Department of Family & Community Health, College of Medicine, Sultan Qaboos University, Oman

Date of Web Publication31-Jul-2012

Correspondence Address:
Thord Theodorson
P.O. Box 35, Al Khod 123
Oman
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 23012206

Rights and PermissionsRights and Permissions
   Abstract 

An account is given of recent literature regarding the major cardiovascular risk factors. It considers high blood pressure, high blood cholesterol, smoking, as well as insulin resistance and its metabolic consequences. The focus is on the current available evidence in terms of causal associations of these risk factors with the occurrence of cardiovascular disease, and the evidence of the benefits of risk factor lowering. The multiplicative effect of risk factors and their multifactorial role in the genesis of cardiovascular disease is now firmly established and will affect the mode of approach to preventive measures. The main preventive options currently available are twofold, a population-wide approach and a high risk approach. The suitability of primary health care as one of the main providers of preventive care is today widely acknowledged. The need for cardiovascular risk assessment to be multifactorial and made in terms of overall actual risk is of paramount importance. The implications of this overall issue for countries like those of the Middle East, where the prevalence of cardiovascular disease is on the rise, are of great concern.

Keywords: cardiovascular risk, risk reduction, preventive strategies.


How to cite this article:
Theodorson T. Cardiovascular risk and risk reduction: A review of recent literature. J Fam Community Med 1995;2:19-26

How to cite this URL:
Theodorson T. Cardiovascular risk and risk reduction: A review of recent literature. J Fam Community Med [serial online] 1995 [cited 2019 Dec 15];2:19-26. Available from: http://www.jfcmonline.com/text.asp?1995/2/1/19/98641


   Introduction Top


Atherosclerosis is a very old disease, which has been found in the mummies of Egyptian pharaohs. It is a pathological entity and its clinical counterpart is cardiovascular disease (CVD). Only in recent times have its consequences reached epidemic proportions, mainly in Western affluent societies, although that epidemic is breaking through to other non-Western populations today. The clinical manifestations of atherosclerosis are manifold, but still constitute only the tip of the iceberg. To some extent atherosclerosis is universal, the pathogenesis is complex, but it is likely that more than 90% of the facts about the processes involved are now known, although how these facts fit into an overall comprehensible framework is less understood [1] .

In the developed world cardiovascular disease (CVD) accounts for almost half of all deaths. In some of the countries there has occured a decline in mortality in recent times, whereas in other countries it has increased [2] . When crude death rates drop below 15 per 1000 persons and life expectancy at birth increases to 55-60 years, the proportion of mortality due to CVD approaches 20-25%, and non-communicable diseases become a major public health problem [3] . This has become the case in the Eastern Mediterranean Region [4] . In light of the proportionately large part of the total disease burden, fatal and non-fatal, played by cardiovascular diseases it has become increasingly important to try to forestall that trend.


   The Relation of Exposure to Risk Top


Blood pressure - diastolic:

One of the first studies to implicate blood pressure was the Framingham heart study in the US, wherein a cohort of 5070 men and women aged 30-62 years have been followed up since the late 1940s [5] . In a landmark review of the evidence MacMahon et a1 [6] pooled the results of nine major prospective observational studies, including a total of 420,000 individuals with 843 strokes and 4856 coronary heart diseases (CHD) events as end-points. They had a mean follow-up period of 10 years. By correcting for within-patients fluctuations of diastolic blood pressure (DBP) over time (regression dilution bias) MacMahon et al were able to show that these previous studies had underestimated the true association between DBP and risk of stroke and CHD events by about 60%. Their analysis also showed that within the range of DBP studied (70-110 mmHg) the risk of raised DBP was continuous and graded, without any evidence of any threshold below which lower levels of DBP were not associated with lower risk of stroke and CHD. Thirdly and not the least, prolonged differences over time in DBP of only 5 mmHg was shown to be associated with at least 34% less stroke and at least 20% less risk of CHD. These pooled results of epidemiologic data have come to be an important milestone in the search for evidence, linking blood pressure with risk of CHD and stroke.

Blood pressure - systolic:

The risk marker of blood pressure had for long been thought to be only the level of DBP. The Multiple Risk Factor . Intervention Trial group (MRFIT) study [7] in the US is the largest single cohort study which has ever been done. It was designed as a randomised, multicentre primary prevention trial to study the effect of a risk factor intervention, relating to blood cholesterol, blood pressure and cigarette smoking. An analysis of its data set [8] regarding the association between blood pressure and CHD showed a strong, continuous, and graded relationship of not only DBP but of systolic blood pressure (SBP) as well. In terms of relative risk for CHD, the data show that the lowest risk is seen at levels of less than 120 mmHg for SBP, and less than 80 mmHg for DBP. Furthermore SBP came out as being the stronger predictor for CHD. This finding is also supported by similar results from the Framingham cohorts [5] .

The diet-heart hypothesis and total blood cholesterol:

From the late 1940s onwards an extensive body of scientific knowledge implicates diet rich in animal fat (high-saturated-fat) in the atherosclerotic process, mediated through raised blood cholesterol. It constitutes a wealth of prospective epidemiological studies throughout the world as well as clinical angiographic correlations, postmortem investigations, and animal experiments. Many clinical trials of cholesterol lowering in persons with elevated cholesterol levels, also provide supportive evidence for these causal associations [7],[9],[10],[11] The MRFIT and Framingham data [7],[11] demonstrate once again, as for BP, a strong, continuous, and graded relationship between risk for CHD and level of blood cholesterol, with a clear risk gradient above the level of 4.65mmo1/L. Much in line with MacMahon et al, another group of investigators Law MR et a1 [12] by following up a cohort of 21 520 men, applied similar methodology and their overall findings were, that the observed difference in mortality from CHD, given a difference over time of 0.6 mmol/L in total serum cholesterol concentration, corresponded to 27% lower mortality rate from CHD.

Taken together, these results strongly support the so called 'lipid hypothesis of atherosclerosis'. That theory encompasses the concept that the quantity and composition of the diet's fat content will alter blood total cholesterol and low-density lipoprotein levels (LDL), and this in turn will alter risk of CHD [13].

Smoking:

Cigarette smoking has been consistently related in a dose-responsive manner to the development of fatal and non-fatal CHD events and the available evidence suggests that smoking may act as a triggering effect, rather than as a necessary underlying substrate for CHD [14] . The health hazard of cigarette smoking is now fully documented and the evidence for a causal role in cardiovascular disease is beyond any doubt [15].

Diabetes Mellitus:

Diabetes accelerates atherogenesis and increases the risk of CHD, particularly in women. The age-adjusted mortality rates for CHD are 2-3 times higher for men, and 3-7 times higher for women with diabetes than among people without diabetes [16] . Other macrovascular sequelae are also greatly increased in diabetes. In non-insulin dependent diabetes (NIDDM) the association with heart disease is complex and is thought to be mediated through what has come to be known as 'the insulin resistant syndrome' (see below).

Insulin Resistance

A common clinical observation is the clustering of several risk factors in one individual. Reaven in 1988, postulated that insulin resistance and compensatory hyperinsulinaemia underlie this clustering and he coined the term "Syndrome X" (or the "insulin resistance syndrome") [17] . That term entails the concept of a metabolic syndrome, wherein insulin resistance is the primary event, leading to the secondary events of hyperinsulinaemia, impaired glucose tolerance (IGT), hypertriglyceridaemia, low HDL and hypertension. Insulin resistance can be defined as a state of subnormal biological action of insulin and the defect is primary, tissue specific (mostly involving skeletal muscle) and involves reduced glucose disposal in the skeletal muscle cells [18] .

There is now abundant evidence that the insulin resistance syndrome predisposes individuals to develop this cluster of associated abnormalities that increase the risk of CHD [19] . Insulin resistance may be genetic and/or acquired. A strong genetic basis is suggested by the high prevalence of insulin resistance, diabetes (NIDDM) and cardiovascular risk in certain racial groups, although environmental factors play an important role. [20],[21]

Obesity

Obesity has been associated with the development of insulin resistance [22] , but excessive calorie intake and obesity are not the sole cause, as it has been observed that 25% of non-obese individuals with normal glucose tolerance also have insulin resistance [17] . Kaplan [23] discusses the importance of the distribution of fat (upper body obesity, or central obesity), as opposed to total body fat, as having a stronger association with the development of CHD, mediated through hyperinsulinaemia. Therefore, reference to body mass index alone as an index of obesity is inadequate because this central distribution of fat is most strongly associated with insulin resistance [18] .


   The Multiplicative Effect of Risk Factors Top


Using data from the MRFIT study Stamler and Neaton [8] demonstrate clearly the additional impact blood pressure has on CHD risk, when other risk factors like cholesterol and smoking are present. The impact is not only additive but multiplicative. The evidence is also supported by the Framingham data. This multiplicative effect of the risk factors has important implications for preventive measures.


   The Multifactorial Genesis of CVD Top


It is clear that CVD in general and CHD in particular are multifactorial and their clinical manifestations reflect the interaction of host and environmental factors, nature versus nurture. The WHO MONICA Project has recently published its first results regarding cross sectional surveys of cardiovascular risk factors in various populations of the developed world. The results show that there exists an enormous variation in terms of morbidity caused by these diseases in the developed countries, and that the accepted cardiovascular mortality risk factors do not reflect well the variation in mortality between populations [24],[25] . On a population level the relation of blood pressure and smoking to CHD is found to be irregular, whereas its relation to stroke is much closer, particularly for blood pressure. Regarding blood cholesterol level there is no longer a need to argue that mass CHD in a population can only occur in the presence of elevations of the mean blood cholesterol [26] . The MONICA Project however, does not address the developing world, whereas other recently published papers have, by studies of Asian migrants and other ethnic groups [20],[21],[27],[28],[29] . The findings of these latter papers suggest that insulin resistance with clustering of diabetes, dyslipidaemia (raised triglycerides and low HDL), hypertension and obesity, in those populations, are main risk factors for an ever increasing epidemic of CHD.


   The Benefits of Risk Reduction Top


High blood pressure:

To see whether the observed benefit of lowering DBP by 5-6 mmHg, shown in MacMahon's overviews could be translated into similar results in the known clinical trials at that time, the same group headed by Collins R [30] undertook a similar overview of 14 randomised trials of antihypertensive drugs. It included 37,000 individuals, mean treatment duration 5 years and mean difference in DBP 5-6 mmHg. The result showed that the expected reduction of stroke incidence was borne out by a reduction of 42%, but regarding CHD the expected reduction of 20-25% was only reduced by 14%. Thus the large hypertension intervention trials of the past 20 years have demonstrated a disappointing effect in terms of lowering cardiovascular risk, except for stroke. Several possible explanations for this have been put forward. Firstly, the adverse effects of the antihypertensive agents used in these trials (mainly betablockers and diuretics) on the blood lipid profile and other metabolic variables such as glucose and potassium [31],[32] . Secondly, the multifactorial effect of the insulin resistance syndromel [7] . Thirdly, a delay of the full benefit of the antihypertensive treatment given is possible, given too short a follow up period of the trials. [33]

High blood cholesterol:

In order to estimate whether lowering of blood cholesterol could actually reproduce the results of their earlier overview, Law et al pooled the results of 10 large prospective (cohort) studies, three international prospective (epidemiological) studies and 28 randomised controlled (interventive) studies [34] . The 10 cohort studies included 494,804 men and recorded 18,811 CVD events, whereas the 28 randomised clinical trials included 46,254 men and recorded 4241 events. The analysis of the 10 cohort studies concluded that a 10% (0.6 mmol) reduction in total cholesterol translates into a 50% reduction in the risk of CHD at the age of 40, successively diminishing in benefit as age increases, to 40% at 50 years and 30% at 60 years of age. The overall results of 27% from their earlier study [12] was largely borne out by their pooled analysis.

Insulin resistance:

If the present observational epidemiologic evidence regarding the joint risk effect of the metabolic consequences of insulin resistance and obesity hold true, then the rationale of reducing central obesity and increasing physical activity becomes obvious [11],[21],[27]. But to that end there do not exist any controlled clinical interventive trials to this day.

Smoking:

The excess cardiovascular risk associated with cigarette smoking has been shown to decrease markedly after quitting smoking, in primary as well as secondary prevention [14],[15].

Regression of atherosclerosis:

What is the evidence for regression of atherosclerosis? Adequately controlled, serial coronary angiographic studies have been appearing in the literature since 1984. Most of them have focused on lipid modification by drugs, although a few have dealt with life style changes. In a recent overview of eight key serial angiographic trials relating to lipid intervention Howes LG et al show that stabilisation or regression of atherosclerosis does occur with the use of lipid-regulating therapy. [35],[36] These authors also state that some trial results show that this may translate into improved clinical outcomes.


   Preventive Strategies Top


Rose G [37] came forward with the terms of 'population strategy' versus 'high-risk strategy'. The variance between populations in terms of population average demonstrates how the distribution curve of the various risks within each population is simply a function of its population mean and those individuals who deviate are simply the tail of the population's own distribution. From this line of reasoning it follows that preventive measures can be laid out as a two-pronged strategy, shifting the whole distribution curve downwards, to the left, or shifting high-risk individuals out of the danger zone (see diagram).



There is now a converging consensus internationally that the two-pronged preventive strategy, as outlined by Rose, is the most cost-effective strategy available today.

International and national bodies have identified primary health care (PHC) as the appropriate setting in which to implement this strategy [38],[39],[40] . The personnel in PHC are well placed in order to use the opportunities of clinical contacts to identify individuals, who are at special risk for future disease. Rose G [41] argues that the implication of this is an uncomfortable one for many countries; namely, the effective delivery of preventive medicine to individuals requires an efficient system of PHC.


   Risk Assessment Top


Putting the high risk strategy into action entails sorting out those who are high risk cases. Apart from deciding on the appropriate cut-off level between cases and non-cases in terms of a specific risk factor, we are faced with the dilemma of assessing the individual's actual risk of future disease. It has been high-lighted recently how imperative it is to assess cardiac risk in terms of overall risk, taking into account the multiplicative effects of the known risk factors, as well as aiming for those with the highest risk [32],[39],[42],[43],[44],[45]


   Conclusion and Recommendations Top


An account has been given of the cumulative and the impressive evidence of the major cardiovascular risks. The major risk factors have been delineated and evidence given for their continuous and graded effect on CVD risk. The common occurrence of clustering of these major risk factors in the individual has been pointed out, as well as their joint multiplicative deleterious effect in terms of increased incidence of CVD.

The overall strategy in combating the cardiovascular diseases has been portrayed as a population versus high-risk strategy. Heart disease incidence depends on how people live, and so it follows that progress in prevention depends on social, economic, and political decisions; as well as on the successful communication of our medical knowledge. By sound impartial advice, physicians can guide and assist in those decisions. Primary health care is well suited as a venue to that end. The need for a multifactorial approach is stressed, as well as an assessment of the overall cardiovascular risk in as much a quantitative and real terms as possible.

Many of the developing countries, like those of the Middle East, have experienced rapid socioeconomic changes over the last two decades and most of the aforementioned risk factors have become highly prevalent. For instance, obesity, high blood pressure, high blood cholesterol and diabetes are increasingly encountered. The prevalence of diabetes is among the highest in the world in the Arabian peninsula [46],[47] Apart from excessive caloric intake and sedentary life-style, cigarette smoking is an important health hazard issue to address.

An effective infrastructure within primary health care, along with population-wide health counselling is of primary importance, in regard to counteracting the deleterious long-term effects and premature death of cardiovascular disease.

In a second paper the present author will describe how, the department of Family and Community Health at the Sultan Qaboos University in Oman, addresses the practicalities of implementing a preventive strategy along the lines presented in this review.

 
   References Top

1.Davies MJ. Atherosclerosis. Br Heart J 1993;G9(Suppl):SI.  Back to cited text no. 1
    
2.Opez AD. Assessing the burden of mortality from cardiovascular diseases. World Health Star. Q 1993;46:91-96.  Back to cited text no. 2
    
3.Dodu SRA. Emergence of cardiovascular disease in developing countries. Cardiology 1988;75:5G-G4.  Back to cited text no. 3
    
4.Alwan AAS. Cardiovascular diseases in the Mediterranen Region. World Health Star. Q 1993;46:97-100.  Back to cited text no. 4
    
5.Stokes J, Kannel WB, Wolf PA, D'Agostino RB, and Cupples LA. Blood Pressure as a Risk Factor for Cardiovascular Disease. The Framingham Study-30 Years of Follow-up. Hypertension 1989;13(suppl I):13-18.  Back to cited text no. 5
    
6.MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Par 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.  Back to cited text no. 6
    
7.Neaton DN, Wentworth D. Multiple Risk Factor Intervention Trial Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Arch Interm Med 1992;152:56-64.  Back to cited text no. 7
    
8.Stamler J, Neaton, Stamler R, Neaton DN. Blood Pressure, Systolic and Diastolic, and Cardiovascular Risks. Us Population Data. Arch Interm Med 1993;153:598-615.  Back to cited text no. 8
    
9.AKushi LH, Kottke TE. Dietary fat and coronary heart disease: Evidence of a Causal Relation. In: Goldbloom RB, Lawrence RS, (eds), Preventing Disease. Beyond the Rhetoric, pp 385-400.  Back to cited text no. 9
    
10.Stamler J, Stamler R, Brown V, Gotto AM, Greenland P, Grundy S, et al. Serum Cholesterol. Doing the Right Thing. Circulation 1993;88:1954-G0.  Back to cited text no. 10
    
11.Kannel WB, Cholesterol and Risk of Coronary Heart Disease and Mortality in Men. Clinical Chemistry 1988;34(8):53-59.  Back to cited text no. 11
    
12.Law MR, Wald NJ, Wu T, Hackshaw A, and Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study, BMJ 1994;308:363-GG.  Back to cited text no. 12
    
13.Davies MJ, Woolf N. Atherosclerosis: what is it and why does it occur? Br Heart J 1993;69 (Suppl):S3-S 11.  Back to cited text no. 13
    
14.Goldberg RJ, Coronary heart disease: Epidemiology and risk factors. In:Ockene IA, Ockene JK, eds. Prevention of coronary heart disease. Boston: Little Brown and Company; 1992.  Back to cited text no. 14
    
15.Do11 R, Peto R, Wheatley K, Gray R, and Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-11.  Back to cited text no. 15
    
16.Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Conor GT, et al. The primary prevention of myocardial infarction. N Engl J Med 1992;326:1406-16.  Back to cited text no. 16
    
17.Reaven GM, Banting Lecture 1988. Role of Insulin Resistance in Human Disease. Diabetes 1988;37:1595-1607.  Back to cited text no. 17
    
18.Williams B. Insulin resistance: the shape of things to come. Lancet 1994;344:521-24.  Back to cited text no. 18
    
19.Reaven GM, Laws A. Diabetologia 1994;37:948-52.  Back to cited text no. 19
    
20.Dhawan J, Bray CL, Warburton R, Chamhir DS, and Morris J. Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians Genetic or environmental effect? Br Heart J 1994;72:413-21.  Back to cited text no. 20
    
21.Li N, Tuomilehto J, Dowse G, Virtala E and Zimmet P. Prevalence of coronary heart disease indicated by electrogram abnormalities and risk factors in developing countries. J Clin Epidermiol 1994;47:599-611.  Back to cited text no. 21
    
22.DeFronzo RA, Pathogenesis of Type 2(non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologica 1992;35:389-97.  Back to cited text no. 22
    
23.Kaplan NM. The Deadly Quartet. Upper-Body Obesity, Glucose Intolerance, Hypertriglyceridae­mia, and Hypertension. Arch Interm Med 1989;149:1514-20.  Back to cited text no. 23
    
24.Bonita R. The MONICA project comes of age. BMJ 1994;309:684-85.  Back to cited text no. 24
    
25.World Health Organisation MONICA project (Prepared by Stewart AW, Kuulasmaa K, Beaglehole R). Ecological analysis of the association between mortality and major risk factors of cardiovascular disease. Int J Epidemiol 1994;23:505-1G.  Back to cited text no. 25
    
26.Rose G. Causes of the trends and variations in CHD mortality in different countries. Int J Epidemiol 1989;18 (Suppl 1):S174-S179.  Back to cited text no. 26
    
27.McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991;337:382-86.  Back to cited text no. 27
    
28.Heller R. INCLEN Multicentre Collaborative Group. Risk factors for cardiovascular disease in the developing world. A multicentre collaborative study in the International Clinical Epidemiology Network (INCLEN). J Clin Epidemiol 1992;45:841-47.  Back to cited text no. 28
    
29.Zimmet PZ, Collins VR, Dowse GK, Alberti KGMM, Tuomilehto J, Knight LT et al. Is hyperinsulinaemia a central characteristic of a chronic cardiovascular risk factor clustering syndrome? Mixed findings in Asian Indian, Creole and Chinese Mauritians. Diabetes medicine 1994;11:388-96.  Back to cited text no. 29
    
30.Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.  Back to cited text no. 30
    
31.Kaplan NM. Cardiovascular Risk Reduction: The Role of Antihypertensive Treatment. The American J of Medicine 1991;90:(suppl 2A)2A-19S-20S.  Back to cited text no. 31
    
32.Poulter N. Management of multiple risk factors for coronary heart disease in patients with hypertension. Am Heart J 1991;121:246-50.  Back to cited text no. 32
    
33.Collins R, Pete, R, Godwin J, and MacMahon S. Blood Pressure and coronary heart disease. Lancet 1990;336:370-71.  Back to cited text no. 33
    
34.Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.  Back to cited text no. 34
    
35.Simons LA. Is regression of human atherosclerosis a clinical reality? Med J Aust 1994; 160:531-32.  Back to cited text no. 35
    
36.Howes LG, Simons LA. Efficacy of drug intervention for lipids in the prevention of coronary artery disease. Aust N Z J Med 1994;24 Supp1:107-112.  Back to cited text no. 36
    
37.Rose G. The Strategy of Preventive medicine. Oxford University Press, 1992.  Back to cited text no. 37
    
38.Report of the U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. Washington, DC: U.S. Department of health and Welfare Service, 1989.  Back to cited text no. 38
    
39.Working Group of the Coronary Prevention Group and the British Heart Foundation. An action plan for preventing coronary heart disease in primary care. BMJ 1991;303:748-50.  Back to cited text no. 39
    
40.Community Prevention and Control of Cardiovascular Diseases. Report of a WHO Expert Committee. WHO Technical Report Series 732. Geneva: Worl Helath Organization, 1986.  Back to cited text no. 40
    
41.Rose G. Preventive Cardiology: What lies ahead? Preventive Medicine 1990;19:97-104.  Back to cited text no. 41
    
42.Kaplan NM, Weidmann P. Is hypertension a metabolic disease? Am Hear J 1993;125:1485-7.  Back to cited text no. 42
    
43.Jackson R, Barham P, Bills J, Birch T, McLennan L, MacMahon S, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993;307:107-10.  Back to cited text no. 43
    
44.Alderman MH. Blood Pressure Management: Individualized Treatment Based on Absolute Risk and the Potential for Benefit. Ann Interm Med 1993;119:329-335.  Back to cited text no. 44
    
45.Whelton PK. Epidemiology of hypertension. Lancet 1994;344:101-6.  Back to cited text no. 45
    
46.Asfour MG, Samantray SK, Dua A, King H. Diabetes Mellitus in Oman. Diabetic Medicine 1991;8:76-80.  Back to cited text no. 46
    
47.Asfour MG. Diabetes Mellitus in the Sultanate of Oman. International Diabetes Digest 1993;4(2):43-46.  Back to cited text no. 47
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    The Relation of ...
    The Multiplicati...
    The Multifactori...
    The Benefits of ...
    Preventive Strat...
   Risk Assessment
    Conclusion and R...
    References

 Article Access Statistics
    Viewed1386    
    Printed87    
    Emailed0    
    PDF Downloaded142    
    Comments [Add]    

Recommend this journal

Advertise | Sitemap | What's New | Feedback | Disclaimer
© Journal of Family and Community Medicine | Published by Wolters Kluwer - Medknow
Online since 05th September, 2010